tolterodine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2705	124937-51-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tolterodine tolterodine tartrate (+)-Tolterodine (R)-Tolterodine	An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE. Molecular weight: 325.50 Formula: C22H31NO CLOGP: 5.24 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 23.47 ALOGS: -4.78 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tolterodine
tolterodine tartrate
(+)-Tolterodine
(R)-Tolterodine

An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE.

Molecular weight: 325.50
Formula: C22H31NO
CLOGP: 5.24
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 23.47
ALOGS: -4.78
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	12 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	24.58 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 25, 1998	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	106.58	11.74	276	22101	223744	50359003
Sensitivity to weather change	96.58	11.74	49	22328	5952	50576795
Dry mouth	84.72	11.74	114	22263	56064	50526683
Multiple sclerosis relapse	80.28	11.74	97	22280	42867	50539880
Multiple sclerosis	80.22	11.74	69	22308	20424	50562323
Urinary incontinence	70.31	11.74	74	22303	28134	50554613
Fall	65.46	11.74	307	22070	334625	50248122
Maternal exposure during pregnancy	55.27	11.74	4	22373	159774	50422973
Pollakiuria	53.18	11.74	59	22318	23792	50558955
Systemic lupus erythematosus	50.17	11.74	3	22374	140619	50442128
Antinuclear antibody negative	46.10	11.74	12	22365	204	50582543
Contraindicated product administered	45.57	11.74	6	22371	148952	50433795
Coombs positive haemolytic anaemia	45.17	11.74	13	22364	326	50582421
Bladder disorder	41.46	11.74	31	22346	7512	50575235
Nocturia	40.02	11.74	29	22348	6701	50576046
Herpes simplex reactivation	38.88	11.74	12	22365	385	50582362
Treatment failure	38.79	11.74	7	22370	137630	50445117
Hypertonic bladder	35.60	11.74	20	22357	2980	50579767
Off label use	35.23	11.74	101	22276	474325	50108422
Exposure during pregnancy	34.43	11.74	6	22371	121009	50461738
Cerebrovascular accident	31.68	11.74	103	22274	94577	50488170
Paranoia	31.00	11.74	30	22347	10318	50572429
Stress urinary incontinence	30.73	11.74	16	22361	2049	50580698
Glossodynia	30.23	11.74	7	22370	115562	50467185
Hallucination, auditory	30.09	11.74	30	22347	10698	50572049
Infusion related reaction	29.96	11.74	19	22358	169538	50413209
Drug intolerance	29.53	11.74	32	22345	219072	50363675
Urinary retention	29.05	11.74	46	22331	26144	50556603
Micturition urgency	28.68	11.74	26	22351	8238	50574509
Gastritis haemorrhagic	27.77	11.74	13	22364	1324	50581423
Balance disorder	27.51	11.74	81	22296	70509	50512238
Bladder spasm	26.94	11.74	13	22364	1417	50581330
Gastrooesophageal reflux disease	26.33	11.74	84	22293	76344	50506403
Antiphospholipid syndrome	26.21	11.74	13	22364	1504	50581243
Transient ischaemic attack	25.81	11.74	49	22328	32161	50550586
Hyperlipidaemia	25.59	11.74	35	22342	17455	50565292
Coronary artery disease	24.79	11.74	46	22331	29680	50553067
Depression	24.13	11.74	140	22237	165283	50417464
Wound	22.98	11.74	9	22368	105785	50476962
Dizziness	22.97	11.74	244	22133	346125	50236622
Complex regional pain syndrome	22.87	11.74	13	22364	1980	50580767
Oesophagitis	21.45	11.74	28	22349	13355	50569392
Abdominal discomfort	20.49	11.74	45	22332	231596	50351151
Hypothyroidism	20.38	11.74	46	22331	34079	50548668
Toxicity to various agents	19.02	11.74	41	22336	212458	50370289
Gait disturbance	18.74	11.74	122	22255	149883	50432864
Mental status changes	18.53	11.74	46	22331	36226	50546521
Urge incontinence	18.19	11.74	8	22369	705	50582042
Completed suicide	18.05	11.74	19	22358	131870	50450877
Anxiety disorder	17.79	11.74	14	22363	3659	50579088
Infection	17.53	11.74	31	22346	172923	50409824
Swelling	16.97	11.74	40	22337	200832	50381915
White blood cell count abnormal	16.73	11.74	16	22361	5424	50577323
Secondary progressive multiple sclerosis	16.56	11.74	9	22368	1257	50581490
Iliac artery occlusion	16.36	11.74	5	22372	155	50582592
Barrett's oesophagus	16.09	11.74	7	22370	601	50582146
Constipation	15.82	11.74	138	22239	185570	50397177
Drug hypersensitivity	15.77	11.74	175	22202	250835	50331912
Neutrophil count abnormal	15.55	11.74	11	22366	2448	50580299
Osteonecrosis	15.33	11.74	32	22345	22485	50560262
Confusional state	15.24	11.74	137	22240	185791	50396956
Pericarditis	15.05	11.74	8	22369	78681	50504066
Dysphagia	15.01	11.74	71	22306	77447	50505300
Drug abuse	14.92	11.74	4	22373	59842	50522905
Therapy non-responder	14.85	11.74	53	22324	50969	50531778
Myocardial infarction	14.74	11.74	78	22299	88949	50493798
Incontinence	14.63	11.74	20	22357	9965	50572782
Neutropenia	14.56	11.74	27	22350	147938	50434809
Stomatitis	14.55	11.74	14	22363	101330	50481417
Hepatic enzyme increased	14.49	11.74	24	22353	137356	50445391
Malignant neoplasm progression	14.46	11.74	6	22371	68118	50514629
Peritonitis	14.23	11.74	25	22352	15461	50567286
Pain	14.19	11.74	176	22201	578727	50004020
Neurogenic bladder	14.07	11.74	11	22366	2846	50579901
Aphonia	13.99	11.74	18	22359	8460	50574287
Product complaint	13.92	11.74	21	22356	11445	50571302
Varicose ulceration	13.89	11.74	6	22371	506	50582241
Haemoglobin abnormal	13.61	11.74	13	22364	4399	50578348
Cardiac failure congestive	13.33	11.74	73	22304	84309	50498438
Body temperature fluctuation	12.88	11.74	9	22368	1964	50580783
Visual impairment	12.83	11.74	62	22315	68213	50514534
Cystitis	12.72	11.74	46	22331	44518	50538229
Increased appetite	12.64	11.74	17	22360	8344	50574403
Colitis ischaemic	12.42	11.74	18	22359	9465	50573282
Febrile neutropenia	12.34	11.74	15	22362	97652	50485095
Pathological fracture	12.20	11.74	16	22361	7666	50575081
Haemoglobin	11.90	11.74	4	22373	169	50582578
Chronic obstructive pulmonary disease	11.88	11.74	51	22326	53384	50529363

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seronegative arthritis	66.19	14.84	19	6935	905	29566668
Lipoma	58.00	14.84	19	6935	1412	29566161
Dry mouth	53.71	14.84	43	6911	21741	29545832
Fall	45.89	14.84	117	6837	177061	29390512
Urinary incontinence	41.62	14.84	33	6921	16448	29551125
Inflammatory marker increased	40.65	14.84	19	6935	3648	29563925
Prostatic specific antigen increased	40.24	14.84	29	6925	12535	29555038
Pollakiuria	38.76	14.84	32	6922	16884	29550689
Urinary retention	37.94	14.84	42	6912	31856	29535717
Balance disorder	36.91	14.84	44	6910	36126	29531447
Musculoskeletal discomfort	33.44	14.84	20	6934	6321	29561252
Micturition urgency	31.74	14.84	18	6936	5155	29562418
Multiple sclerosis	30.55	14.84	18	6936	5536	29562037
Confusional state	21.07	14.84	72	6882	127805	29439768
Urinary tract infection	20.99	14.84	50	6904	72304	29495269
Failure to thrive	20.72	14.84	16	6938	7668	29559905
Cerebrovascular accident	20.04	14.84	51	6903	76860	29490713
Asthenia	19.58	14.84	101	6853	215149	29352424
Faecaloma	18.96	14.84	12	6942	4190	29563383
Gait inability	18.15	14.84	22	6932	18353	29549220
Blood pressure systolic increased	18.01	14.84	21	6933	16824	29550749
Nocturia	17.46	14.84	15	6939	8347	29559226
Incontinence	16.99	14.84	12	6942	5020	29562553
Rectal tenesmus	16.11	14.84	6	6948	652	29566921
Toxicity to various agents	15.47	14.84	11	6943	173650	29393923
Multiple sclerosis relapse	15.26	14.84	16	6938	11403	29556170
Dizziness	15.19	14.84	86	6868	189598	29377975
Muscular weakness	14.98	14.84	40	6914	62012	29505561

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis	97.56	11.29	68	22307	18873	64457484
Urinary tract infection	95.95	11.29	233	22142	231363	64244994
Sensitivity to weather change	87.67	11.29	44	22331	6670	64469687
Fall	74.73	11.29	314	22061	416512	64059845
Multiple sclerosis relapse	70.56	11.29	79	22296	41056	64435301
Urinary incontinence	68.21	11.29	73	22302	36078	64440279
Dry mouth	59.32	11.29	88	22287	60330	64416027
Pollakiuria	53.12	11.29	60	22315	31470	64444887
Lipoma	49.19	11.29	22	22353	2577	64473780
Cerebrovascular accident	46.15	11.29	128	22247	137455	64338902
Balance disorder	39.64	11.29	89	22286	83837	64392520
Seronegative arthritis	38.85	11.29	19	22356	2724	64473633
Micturition urgency	37.27	11.29	30	22345	10329	64466028
Bladder disorder	35.65	11.29	26	22349	7741	64468616
Toxicity to various agents	33.86	11.29	46	22329	363467	64112890
Urinary retention	33.81	11.29	61	22314	49140	64427217
Off label use	33.10	11.29	111	22264	632695	63843662
Prostatic specific antigen increased	30.73	11.29	25	22350	8735	64467622
Drug abuse	29.87	11.29	5	22370	132369	64343988
Dizziness	27.94	11.29	249	22126	429914	64046443
Stress urinary incontinence	25.46	11.29	12	22363	1586	64474771
Musculoskeletal discomfort	24.11	11.29	29	22346	16248	64460109
Incontinence	23.85	11.29	25	22350	12056	64464301
Hallucination, auditory	23.18	11.29	29	22346	16910	64459447
Maternal exposure during pregnancy	23.07	11.29	3	22372	95881	64380476
Bladder spasm	23.06	11.29	12	22363	1960	64474397
Secondary progressive multiple sclerosis	21.87	11.29	10	22365	1233	64475124
Febrile neutropenia	21.54	11.29	20	22355	187637	64288720
Inflammatory marker increased	21.34	11.29	20	22355	8431	64467926
Confusional state	20.58	11.29	158	22217	260986	64215371
Contraindicated product administered	20.45	11.29	6	22369	107823	64368534
Gait inability	20.07	11.29	45	22330	42323	64434034
Hypertonic bladder	19.32	11.29	13	22362	3405	64472952
Paranoia	19.27	11.29	26	22349	16326	64460031
Drug hypersensitivity	18.80	11.29	144	22231	237671	64238686
Asthenia	18.41	11.29	228	22147	427816	64048541
Gastrooesophageal reflux disease	18.35	11.29	67	22308	83076	64393281
Treatment failure	18.00	11.29	9	22366	116807	64359550
Transient ischaemic attack	17.75	11.29	44	22331	44138	64432219
Exposure during pregnancy	17.37	11.29	3	22372	77672	64398685
Systemic lupus erythematosus	17.35	11.29	3	22372	77609	64398748
Vision blurred	16.84	11.29	69	22306	90247	64386110
Nocturia	16.71	11.29	20	22355	11145	64465212
Mental status changes	15.85	11.29	52	22323	61110	64415247
Aphonia	15.41	11.29	17	22358	8680	64467677
Coronary artery disease	15.32	11.29	51	22324	60382	64415975
Neutrophil count decreased	15.19	11.29	4	22371	77192	64399165
Infusion related reaction	15.09	11.29	21	22354	164446	64311911
Body temperature fluctuation	15.04	11.29	11	22364	3287	64473070
Iliac artery occlusion	14.98	11.29	5	22370	265	64476092
Completed suicide	14.91	11.29	35	22340	224379	64251978
Urge incontinence	14.82	11.29	7	22368	929	64475428
Neutropenia	14.66	11.29	39	22336	239585	64236772
Product complaint	14.07	11.29	19	22356	11935	64464422
Blood pressure systolic increased	13.68	11.29	43	22332	49410	64426947
Cystitis	13.60	11.29	39	22336	42636	64433721
Drug intolerance	13.57	11.29	28	22347	187964	64288393
Bladder adenocarcinoma stage unspecified	13.30	11.29	3	22372	35	64476322
Speech disorder	13.29	11.29	42	22333	48399	64427958
Barrett's oesophagus	12.90	11.29	6	22369	769	64475588
Hand deformity	12.84	11.29	3	22372	62768	64413589
Multiple organ dysfunction syndrome	12.62	11.29	10	22365	101403	64374954
Escherichia urinary tract infection	12.48	11.29	18	22357	12019	64464338
Blood cholesterol increased	12.47	11.29	42	22333	50024	64426333
Psychotic disorder	12.40	11.29	33	22342	34545	64441812
Colitis ischaemic	12.39	11.29	19	22356	13395	64462962
Orthostatic hypotension	12.35	11.29	40	22335	46698	64429659
Dysphagia	12.25	11.29	71	22304	106741	64369616
Stomatitis	12.20	11.29	12	22363	109593	64366764
Body height decreased	12.08	11.29	14	22361	7540	64468817
Malignant neoplasm progression	11.84	11.29	13	22362	112858	64363499
Thrombocytopenia	11.82	11.29	39	22336	223762	64252595
Increased appetite	11.75	11.29	16	22359	10130	64466227
Death	11.73	11.29	109	22266	482596	63993761
Palpitations	11.69	11.29	69	22306	104419	64371938
Hyperlipidaemia	11.56	11.29	25	22350	22951	64453406
Oesophageal stenosis	11.51	11.29	10	22365	3824	64472533

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04BD07	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence
FDA MoA	N0000000125	Cholinergic Muscarinic Antagonists
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:51371	muscle relaxants
CHEBI has role	CHEBI:53784	antispasmodics
FDA EPC	N0000175700	Cholinergic Muscarinic Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Urgent desire to urinate	indication	75088002
Urge incontinence of urine	indication	87557004
Bladder muscle dysfunction - overactive	indication	236633002
Increased Urinary Frequency	indication
Torsades de pointes	contraindication	31722008
Dementia	contraindication	52448006
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Myasthenia gravis	contraindication	91637004	DOID:437
Prolonged QT interval	contraindication	111975006
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Retention of urine	contraindication	267064002
Gastric retention	contraindication	307227006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Gastrointestinal hypomotility	contraindication	421807004
Poor metabolizer due to cytochrome p450 CYP2D6 variant	contraindication	423629005
Congenital long QT syndrome	contraindication	442917000
Aggravated Glaucoma	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.83	acidic
pKa2	9.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	8.49	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	8.57	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.51	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.66	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	7.77	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	8.85	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	8.16	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	8.85	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		Ki	8.15	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR		ACM5_RAT		Ki	8.66	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR		ACM4_RAT		Ki	8.51	CHEMBL

External reference:

ID	Source
4024113	VUID
N0000022118	NUI
D00646	KEGG_DRUG
124937-52-6	SECONDARY_CAS_RN
4021103	VANDF
4024113	VANDF
C0388753	UMLSCUI
CHEBI:9622	CHEBI
CHEMBL1382	ChEMBL_ID
DB01036	DRUGBANK_ID
CHEMBL1722209	ChEMBL_ID
D000068737	MESH_DESCRIPTOR_UI
443879	PUBCHEM_CID
360	IUPHAR_LIGAND_ID
6768	INN_ID
WHE7A56U7K	UNII
119565	RXNORM
191519	MMSL
5600	MMSL
d04294	MMSL
007444	NDDF
007445	NDDF
109113000	SNOMEDCT_US
372570008	SNOMEDCT_US
386971005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Detrol	HUMAN PRESCRIPTION DRUG LABEL	1	0009-4541	TABLET, FILM COATED	1 mg	ORAL	NDA	25 sections
Detrol	HUMAN PRESCRIPTION DRUG LABEL	1	0009-4544	TABLET, FILM COATED	2 mg	ORAL	NDA	25 sections
Detrol LA	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5190	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	NDA	29 sections
Detrol LA	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5191	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	NDA	29 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0010	TABLET, FILM COATED	1 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0018	TABLET, FILM COATED	2 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7163	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7164	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	26 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6592	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	20 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6593	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	20 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-706	TABLET, EXTENDED RELEASE	1 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-707	TABLET, EXTENDED RELEASE	2 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-189	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	20 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-189	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	20 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-190	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	20 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-190	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	20 sections
Tolterodine Tartrate	Human Prescription Drug Label	1	16571-126	TABLET, FILM COATED	1 mg	ORAL	ANDA	21 sections
Tolterodine Tartrate	Human Prescription Drug Label	1	16571-127	TABLET, FILM COATED	2 mg	ORAL	ANDA	21 sections
DETROL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-959	TABLET, FILM COATED	2 mg	ORAL	NDA	23 sections
Tolterodine tartrate	Human Prescription Drug Label	1	27241-191	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections
Tolterodine tartrate	Human Prescription Drug Label	1	27241-192	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	29300-239	TABLET	1 mg	ORAL	ANDA	20 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	29300-240	TABLET	2 mg	ORAL	ANDA	20 sections
Tolterodine Tartrate	Human Prescription Drug Label	1	31722-607	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	Human Prescription Drug Label	1	31722-608	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-805	TABLET, FILM COATED	1 mg	ORAL	ANDA	22 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-806	TABLET, FILM COATED	2 mg	ORAL	ANDA	22 sections
Tolterodine tartrate	Human Prescription Drug Label	1	33342-097	TABLET, FILM COATED	1 mg	ORAL	ANDA	22 sections
Tolterodine tartrate	Human Prescription Drug Label	1	33342-098	TABLET, FILM COATED	2 mg	ORAL	ANDA	22 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	43975-322	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections